Nurix therapeutics reports first quarter fiscal 2023 financial results and provides a corporate update

Licensed to gilead a new development candidate, nx-0479/gs-6791, a targeted protein degrader of irak4, resulting in a $20 million payment
NRIX Ratings Summary
NRIX Quant Ranking